BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 31808281)

  • 1. Securing sustainable funding for viral hepatitis elimination plans.
    Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
    Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Securing wider EU commitment to the elimination of hepatitis C virus.
    Wedemeyer H; Tergast TL; Lazarus JV; Razavi H; Bakoyannis K; Baptista-Leite R; Bartoli M; Bruggmann P; Buşoi CS; Buti M; Carballo M; Castera L; Colombo M; Coutinho RS; Dadon Y; Esmat G; Esteban R; Farran JC; Gillyon-Powell M; Goldberg D; Hutchinson S; Janssen HLA; Kalamitsis G; Kondili LA; Lambert JS; Marinho RT; Maticic M; Patricello A; Peck-Radosavljevic M; Pol S; Poljak M; Pop C; Sokol T; Sypsa V; Tözün N; Younossi Z; Aghemo A; Papatheodoridis GV; Hatzakis A
    Liver Int; 2023 Feb; 43(2):276-291. PubMed ID: 36196744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of HCV in Russia: Barriers and Perspective.
    Isakov V; Nikityuk D
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatitis C in a psychiatric setting: A forgotten reservoir?].
    Rolland B; Bailly F; Cutarella C; Drevon O; Carrieri P; Darque A; Hallouche N; Maptue N; Pol S; Llorca PM; Lang JP
    Encephale; 2021 Apr; 47(2):181-184. PubMed ID: 32473777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Elimination of hepatitis C virus in Denmark].
    Døssing A; Røge BT; Madsen LG; Laursen AL; Hansen JB; Bukh J; Weis N
    Ugeskr Laeger; 2020 Feb; 182(9):. PubMed ID: 32138816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global reporting of progress towards elimination of hepatitis B and hepatitis C.
    Cui F; Blach S; Manzengo Mingiedi C; Gonzalez MA; Sabry Alaama A; Mozalevskis A; Séguy N; Rewari BB; Chan PL; Le LV; Doherty M; Luhmann N; Easterbrook P; Dirac M; de Martel C; Nayagam S; Hallett TB; Vickerman P; Razavi H; Lesi O; Low-Beer D
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):332-342. PubMed ID: 36764320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy for the Elimination of Hepatitis C in Cantabria.
    Crespo J; Tejerina Puente A; Cuadrado A; Llerena S; Cabezas J;
    Rev Esp Enferm Dig; 2020 Jul; 112(7):565-570. PubMed ID: 32543873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions.
    Duffell EF; Hedrich D; Mardh O; Mozalevskis A
    Euro Surveill; 2017 Mar; 22(9):. PubMed ID: 28277217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
    Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
    BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review.
    Greenaway C; Makarenko I; Chakra CNA; Alabdulkarim B; Christensen R; Palayew A; Tran A; Staub L; Pareek M; Meerpohl JJ; Noori T; Veldhuijzen I; Pottie K; Castelli F; Morton RL
    Int J Environ Res Public Health; 2018 Sep; 15(9):. PubMed ID: 30223539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
    Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
    World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
    van Dijk M; Drenth JPH;
    J Viral Hepat; 2020 Dec; 27(12):1270-1283. PubMed ID: 32964615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy.
    Lazarus JV; Picchio CA; Guy D; Aleman S; James C; Nava FA; Øvrehus A; Turnes J; Ward JW; Ustianowski A
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101564. PubMed ID: 33740477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
    Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
    BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.